Telix Pharmaceuticals Limited (TLX,TLX.AX) announces that the U.S. Food and Drug Administration has accepted the Biologics License Application or BLA for its breakthrough investigational kidney cancer PET1 imaging agent TLX250-CDx (Zircaix2, 89Zr-DFO-girentuximab). The FDA granted a Priority Review and provided a PDUFA3 date of 27 August 2025, paving the way for a U.S. commercial launch in 2025.
If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common and one of the most aggressive sub-types of kidney cancer, the company said in a statement.
TLX closed Tuesday's regular trading at $19.50 down $1.43 or 6.83%. But in the after-hours trading, the stock gained $0.89 or 4.56%.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.